Investor Relations

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.

Ideaya Highlights

Investor Presentation

Download PDF

Recent News

Investor Alerts

Dec 2, 2024

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor...

Nov 29, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on November 27, 2024, the...

Nov 18, 2024

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial...

All Releases

Events

7th Annual Evercore HealthCONx Conference

Wednesday, December 4, 2024

1:20pm EST

Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Jonathan Miller, Managing Director, Biotech and Pharma Equity Research

Add to Calendar

Set Email Reminder

IDEAYA Biosciences Investor R&D Day

Monday, December 16, 2024

8:00am EST

Pre-registration is available through the following link: https://lifescievents.com/event/ideaya-4/

Add to Calendar

Set Email Reminder

All Events

Investor Resources